Comprehensive toxicity profile of the 4AC-4THP neoadjuvant regimen in HER2-positive breast cancer: a multicenter real-world study in Vietnam

The 4AC-4THP neoadjuvant regimen in HER2-positive breast cancer showed acceptable tolerability in Vietnamese patients, especially among younger, low-comorbidity Asian populations. Subclinical cardiac dysfunction was common but mild and manageable. These findings provide further support for its use in neoadjuvant settings with appropriate monitoring strategies, especially in real-world clinical settings with variable access to monitoring resources.